Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04534491 · ClinicalTrials.gov registry record · Phase 3

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

A Phase 3 study, sponsored by Bayer.

Completed
Registry status
Phase 3
Development phase
855
Enrollment target

NCT04534491 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 855 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04534491, a Phase 3 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 3
Development phase
855 participants
Enrollment target

Study Summary

With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional. An area of focus was on the potential benefits of an over-the-counter status for Oxytrol and on the ongoing use behavior of the consumers. Oxytrol is a thin, flexible, clear patch that is indicated for the treatment of overactive bladder a disease characterized by a collection of symptoms, including urinary frequency, urgency, and urge incontinence. The adhesive patch is placed on the skin to deliver Oxytrol through the skin into the bloodstream.

Interventions

  • DRUG Oxybutynin (Oxytrol, BAY839380)

Trial Details

FieldValue
Enrollment Target 855 participants
Start Date 2010-05-25
Est. Completion 2011-06-22
Phase Phase 3

Sponsor

Bayer

591 total trials

What the Registry Record Tells You About NCT04534491

The ClinicalTrials.gov registry entry for NCT04534491 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 855 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Oxybutynin (Oxytrol, BAY839380) is the first listed.

NCT04534491 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04534491 about?

NCT04534491 is a clinical study titled "Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.". With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional. An area of focus was on the potential benefits of an over-the-counter s...

What is the current status of trial NCT04534491?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 855 participants. The study started on 2010-05-25. Estimated completion is 2011-06-22.

What interventions are being tested in trial NCT04534491?

The interventions under investigation include: Oxybutynin (Oxytrol, BAY839380) (DRUG).

Who is sponsoring clinical trial NCT04534491?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.